- Home
- IZEA vs COCH Comparison
IZEA vs COCH Comparison
Compare IZEA & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IZEA | COCH |
|---|---|---|
| Founded | 2006 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 51.0M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IZEA | COCH |
|---|---|---|
| Price | $2.59 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 28.8K | ★ 49.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 17.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,099,695.00 | $241,000.00 |
| Revenue This Year | $20.81 | $1.58 |
| Revenue Next Year | $14.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $2.52 | $0.36 |
| 52 Week High | $5.86 | $1.89 |
Technical Indicators
Market Signals| Indicator | IZEA | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 29.61 | 49.33 |
| Support Level | N/A | $0.63 |
| Resistance Level | $3.85 | $0.74 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 13.73 | 46.56 |
Price Performance
Historical ComparisonAbout IZEA IZEA Worldwide Inc.
IZEA Worldwide Inc is a full-service creator economy agency powered by proprietary ZED technology, with a mission to make Creator Economy solutions for marketers. It does this by lighting up the Creator Economy with IZEA's strategies, campaigns, and solutions that build brands and drive demand. Since launching the industry's first-ever influencer marketing platform in 2006, IZEA has facilitated nearly 4 million collaborations between brands and creators.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.